FDA to review flu vaccine it had previously rejected
The FDA will advance its review of Moderna’s previously rejected flu vaccine after the company met with regulators and amended its application. Moderna proposes full approval for ages 50–64 and accelerated approval for those 65 and older with a required additional study in older adults.
